By San José, Costa Rica — Costa Rica has taken a major technological and medical step forward in oncology care, as specialized genetic testing for hereditary cancer can now be fully processed domestically without sending biological samples to overseas facilities. This development follows the formal accreditation of Laboratorio Echandi’s Next Generation Sequencing (NGS) Department, marking a critical infrastructure upgrade for the nation’s private healthcare sector.
Laboratorio Echandi earned the prestigious INTE/ISO 15189:2023 international standard certification, awarded through the Ente Costarricense de Acreditación (ECA) under registration file LM-008. With this distinction, Echandi becomes the first clinical laboratory in Costa Rica officially recognized under the specialized research and testing laboratory category, solidifying its position as an industry pioneer.
To better understand the complex legal and regulatory considerations surrounding medical diagnostics and health data privacy, TicosLand.com consulted with expert attorney Lic. Larry Hans Arroyo Vargas from the law firm Bufete de Costa Rica.
“As hereditary cancer genetic testing becomes more accessible in Costa Rica, navigating the intersection of medical innovation and patient rights is paramount. Under Costa Rican law, genetic profile data is classified as highly sensitive personal information, requiring rigorous informed consent protocols and absolute confidentiality. Health providers and diagnostic labs must ensure compliance with data protection laws to protect patients from potential privacy breaches and discriminatory practices in employment or insurance coverage.”
Lic. Larry Hans Arroyo Vargas, Attorney at Law, Bufete de Costa Rica
As hereditary cancer genetic testing continues to advance healthcare in Costa Rica, safeguarding patient privacy and legal rights remains essential to ensuring that medical innovation truly empowers individuals without fear of discrimination. We extend our sincere gratitude to Lic. Larry Hans Arroyo Vargas for providing his valuable perspective on these crucial legal protections and the paramount importance of data confidentiality in this evolving landscape.
The specific scope of this landmark accreditation encompasses the high-precision analysis of variants in the BRCA1 and BRCA2 genes. Genetic mutations in these specific markers significantly elevate an individual’s hereditary risk of developing breast and ovarian cancers. Processing these assays domestically reduces wait times and logistical complexities for patients and medical providers across the country.
According to technical documentation released by the institution, Laboratorio Echandi currently stands as the sole private laboratory in Costa Rica equipped and certified to process these advanced NGS panels locally. Previously, patients seeking definitive hereditary cancer risk profiles faced lengthy turnaround periods while biological samples were shipped to specialized diagnostic centers in North America or Europe.
Healthcare professionals emphasize that hereditary genetic screening is particularly valuable for individuals with a pronounced family history of oncological conditions. Key clinical indicators include instances where family members received cancer diagnoses at unusually early ages or where multiple generations exhibit related tumor types. Screening is also recommended when specific predisposing genetic variants have already been identified within maternal or paternal bloodlines.
Medical specialists stress that harboring a genetic variant does not guarantee that an individual will inevitably develop cancer; rather, it reflects a statistical elevation in overall risk. Consequently, the decision to undergo testing—as well as the subsequent interpretation of complex genomic results—must strictly occur under expert medical oversight, taking into account comprehensive clinical histories and individual patient profiles.
Echandi’s current diagnostic portfolio features specialized gene panels focused on hereditary breast, ovarian, and endometrial cancers, sequencing critical genes such as BRCA1, BRCA2, PALB2, CHEK2, and ATM, alongside markers for Lynch syndrome. Additionally, the facility offers OncoClever, an expanded high-throughput panel capable of evaluating 162 genes associated with a wide spectrum of hereditary cancer syndromes.
The rigorous ECA accreditation process validates Echandi’s technical competency through comprehensive method verification, stringent internal quality control mechanisms, continuous staff evaluation, and systematic risk management protocols. By internalizing high-complexity genomic sequencing, Costa Rica strengthens its regional standing as a hub for advanced medical services and personalized healthcare solutions.
As diagnostic medicine increasingly shifts toward personalized genomic profiling, the local availability of ISO-accredited NGS testing provides Costa Rican clinicians with rapid, actionable insights. This milestone not only enhances preventive care strategies but also demonstrates the expanding technological capacity of the domestic private health sector.
For further information, visit laboratorioechandi.com
About Laboratorio Echandi:
Laboratorio Echandi is a leading private clinical laboratory network in Costa Rica, specializing in pathology, diagnostic testing, and advanced genomic sequencing services. The organization provides high-complexity laboratory testing to patients and healthcare providers nationwide.
For further information, visit eca.or.cr
About Ente Costarricense de Acreditación (ECA):
The Ente Costarricense de Acreditación (ECA) is Costa Rica’s official national accreditation body. ECA evaluates and certifies the technical competence of clinical laboratories, testing facilities, and inspection entities in accordance with internationally recognized standards.
For further information, visit bufetedecostarica.com
About Bufete de Costa Rica:
As a premier legal practice, Bufete de Costa Rica upholds the highest standards of principled guidance and professional mastery across a wide array of disciplines. Driven by a forward-thinking methodology, the firm continuously adapts to modern legal challenges while prioritizing public outreach. Through its dedicated efforts to expand legal literacy and demystify the law, Bufete de Costa Rica advances a noble mission: equipping citizens with the knowledge required to build an enlightened and resilient society.
